Atopic Dermatitis News and Research

RSS

Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.

12 Oct 2011

Creabilis receives $20 million in Series B funding

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures.

4 Oct 2011

Invida, Sinclair IS launch two dermatology products in seven Asia-Pacific markets

Sinclair IS Pharma Plc, the international specialty pharmaceutical company, and Invida Holdings Private Limited, a leader in the commercialisation of specialty biopharmaceutical and healthcare products throughout Asia Pacific, announce that their partnership has already led to the launch of two Sinclair IS dermatology products in seven Asia-Pacific markets.

30 Sep 2011

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.

26 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

New corticosteroid with cream-like base

Upsher-Smith Laboratories, Inc. announced the launch of Trianex 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment.

11 Jul 2011

Provectus presents additional data on PV-10 at two separate melanoma conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.

30 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Anacor Pharmaceuticals announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis.

28 Jun 2011

Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.

16 Jun 2011

Invida announces launch of novel atopic dermatitis symptomatic treatment

Invida Group Private Limited reaffirmed its commitment to patients in Asia Pacific by announcing the launch of a novel atopic dermatitis symptomatic treatment, Atopiclair, which will be available to patients across Asia in second half of 2011.

26 May 2011

Gerber Products receives first qualified health claim from FDA for infant formulas

Today, Gerber Products Company, a part of the Nestlé family, announced that Gerber Good Start milk-based formulas are the first and only infant formulas that meet the criteria for a qualified health claim.

26 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

Anacor first quarter revenues increase to $2.2 million

Anacor Pharmaceuticals reviewed today its first quarter accomplishments and reported financial results for the quarter ended March 31, 2011.

5 May 2011

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

ProtoKinetix, is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market.

27 Apr 2011

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

27 Apr 2011

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will present data on two of its compounds at the following conferences: “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”.

25 Apr 2011

Psoriasis patients still need long-established treatment alternatives

For patients with severe psoriasis, a new class of intravenous and injectable biological medicines known as "biologics" has brought about a near revolution in treatment.

21 Apr 2011

Atopic Dermatitis News and Research

Further Reading

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Creabilis receives $20 million in Series B funding

Invida, Sinclair IS launch two dermatology products in seven Asia-Pacific markets

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

New corticosteroid with cream-like base

Provectus presents additional data on PV-10 at two separate melanoma conferences

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences

Invida announces launch of novel atopic dermatitis symptomatic treatment

Gerber Products receives first qualified health claim from FDA for infant formulas

Lx Therapies, BioCis partner to form Laurantis Pharma

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor first quarter revenues increase to $2.2 million

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Psoriasis patients still need long-established treatment alternatives

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News